Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22399599
PII: 32/3/815
Knihovny.cz E-resources
- MeSH
- Rats MeSH
- Kidney metabolism MeSH
- Rats, Wistar MeSH
- Indium Radioisotopes metabolism MeSH
- Yttrium Radioisotopes metabolism MeSH
- Somatostatin analogs & derivatives metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Indium Radioisotopes MeSH
- Yttrium Radioisotopes MeSH
- Somatostatin MeSH
UNLABELLED: Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As (90)Y emits no gamma rays, absorbed doses for (90)Y are usually estimated using the same peptide labelled with (111)In. The aim of the study was to determine if replacement of (90/88)Y by (111)In affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. MATERIALS AND METHODS: Radiolabelled peptides were administered intravenously to male Wistar rats. RESULTS: The peptides under study labelled either with (111)In or with (88/90)Y showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for (88/90)Y-labeled peptide in comparison with the one of (111)In. CONCLUSION: We conclude that a radiation-absorbed dose after (90)Y-labelled somatostatin analogues appears to be lower than that predicted by the (111)In-labelled peptide.
